Q-omics provides the consensus-scored MSR1 profile across patient tissues and cancer cell-line models. MSR1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MSR1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MSR1 protein abundance shows 31,377 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where MSR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSR1 survival associations across molecular data types. MSR1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSR1 RNA expression–survival associations across cancer types. High MSR1 expression shows unfavorable associations in UVM, ACC, LGG and LAML, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MSR1 RNA expression.
This table summarizes MSR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MSR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSR1 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, KIRP and THCA. The KIRC box plot shows higher MSR1 RNA expression in tumor versus normal tissue (log2 FC = +2.304, t-test p < 0.001).
This table shows molecular features associated with MSR1 in patient tissues and cancer cell lines. In patient samples, MSR1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MSR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
